Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Barnabie C Agatep"'
Autor:
Felix W. Frueh, Ronald E. Aubert, Barnabie C Agatep, Robert R. Verbrugge, A Patel, K A Johansen Taber, C. Sanders, Mona Khalid, Edward J. Stanek, Robert S. Epstein
Publikováno v:
Clinical Pharmacology & Therapeutics. 91:450-458
To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross-sectional, fax-based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303
Autor:
V. Herrera, J Shabbeer, B Schrader, Barnabie C Agatep, E J Stanek, Felix W. Frueh, James J. Devlin, Scott L. Charland, M Ryvkin, H R Superko
Publikováno v:
The pharmacogenomics journal. 14(3)
Despite the clinical benefit of statin therapy and the numerous strategies used to improve adherence, no strategy has used direct communication of genetic test results to the patient as an adherence and persistence motivator. We investigated in a rea
Autor:
S.L. Charland, V. Herrera, B.J. Schrader, G.S. Hawk, Daniel C. Malone, Eric J. Stanek, Barnabie C Agatep
Publikováno v:
Value in Health. 15(7)
Autor:
Scott L Charland, Barnabie C Agatep, Bruce J Schrader, Felix W Frueh, Vivian Herrera, Miriam Ryvkin, Junaid Shabbeer, James J Devlin, Robert H Superko, Eric J Stanek
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 5
Background A recent meta-analysis demonstrated that cardiovascular (CV) events and all-cause mortality are reduced in both sexes with statin therapy. Additionally, the Institute of Medicine and the American College of Cardiology advocate reporting of
Autor:
S.L. Charland, H. Superko, Robert S. Epstein, Barnabie C Agatep, James Devlin, Eric J. Stanek, Felix W. Frueh, V. Herrera
Publikováno v:
Journal of the American College of Cardiology. 59(13)
Numerous strategies to improve statin adherence have been evaluated; however, none have utilized direct patient communication of genetic information as a motivator. This trial is the first to evaluate this novel technique. AKROBATS ([NCT01068834][1])
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 4
OBJECTIVES: Cytochrome P450 2C19 (CYP2C19) genotype has been shown to affect cardiovascular (CV) outcomes for clopidogrel but not prasugrel. This study evaluates the cost-effectiveness of CYP2C19-guided vs. routine antiplatelet therapy in ACS patient
Autor:
Barnabie C Agatep, Cynthia H Ewel, Vivian Herrera, Eric J. Stanek, Scott L. Charland, Nathan J. Markward
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 4
BACKGROUND: Cytochrome P450 2C19 genotype has been shown to modify cardiovascular outcomes on clopidogrel therapy in patients post-acute coronary syndromes or percutaneous coronary interventions. Recent clopidogrel label changes have incorporated thi
Autor:
Robert S. Epstein, Scott L. Charland, Nathan J. Markward, Eric J. Stanek, Robert Superko, James J. Devlin, Barnabie C Agatep, B.J. Schrader, Felix W. Frueh
Publikováno v:
Journal of Clinical Lipidology. 5:223-224
Autor:
A. Powers, Claudio Faria, Richard H. Chapman, R.L. Knoth, Timothy J Inocencio, Michael Johnsrud, Barnabie C Agatep
Publikováno v:
Journal of Clinical Oncology. 32:298-298
298 Background: Research evaluating the impact of different clinical practice patterns according to settings of care and oncology patient outcomes is limited. This study describes chemotherapy-induced nausea and vomiting (CINV) rates in chemotherapy
Autor:
Richard H. Chapman, Barnabie C Agatep, Claudio Faria, R.L. Knoth, Michael Johnsrud, Timothy J Inocencio, A. Powers
Publikováno v:
Journal of Clinical Oncology. 32:297-297
297 Background: Clinical practice may differ according to settings of care and may impact both the quality of care delivered and, ultimately, patient outcomes. This study describes the differences in chemotherapy-induced nausea and vomiting (CINV) ra